When genetics meets destiny: rethinking hypertrophic cardiomyopathy through the lens of genotype

References

[1] Vissing CR,Helms AS.Differences in disease trajectory, comorbidities, and mortality in sarcomeric and nonsarcomeric hypertrophic cardiomyopathy.Circulation2026;153:1104-16

[2] Maron BJ,Casey SA.How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice.JAMA Cardiol2016;1:98-105

[3] Fumagalli C,Beltrami M.Incidence of stroke in patients with hypertrophic cardiomyopathy in stable sinus rhythm during long-term monitoring.Int J Cardiol2023;381:70-5

[4] Kirchhof P,Goette A.Early rhythm-control therapy in patients with atrial fibrillation.N Engl J Med2020;383:1305-16

[5] Harper AR,Grace C.Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity.Nat Genet2021;53:135-42 PMCID:PMC8240954

[6] Mahmoud AK,Sheashaa H.Cardiovascular outcomes following bariatric surgery in obese patients with hypertrophic cardiomyopathy: a multicenter propensity-matched analysis.Am Heart J Plus2026;64:100756 PMCID:PMC13010978

[7] O'Mahony C,Pavlou M.A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).Eur Heart J2014;35:2010-20

[8] Ommen SR,Asif IM.2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.Circulation2024;149:e1239-311

[9] Maurizi N,Biagini E.Hypertrophic cardiomyopathy: prevalence of disease-specific red flags.Eur Heart J2025;46:3082-94